Other languages Aquaporin A/S

Equities

AQP

DK0061555109

Delayed Nasdaq Copenhagen Other stock markets 03:45:21 2024-05-06 EDT			5-day change	1st Jan Change
14.8 ^DKK	+0.34%		+5.71%	-67.83%

04-05	Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
04-05	Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023	04-05
Aquaporin A/S Provides Earnings Guidance for the Year 2024	04-05
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023	03-25
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder	03-25
AstraZeneca Bags US FDA Clearance for Rare Autoimmune Disease Treatment Ultomiris	03-25
AstraZeneca Receives US Approval for Neuromyelitis Optica Spectrum Disorder Treatment	03-25
Aquaporin Announces Changes in Executive Management Team	02-02
Aquaporin A/S Provides Earnings Guidance for the Financial Year 2024	01-29
Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023	11-16
AstraZeneca's Soliris Approved in China for Treatment of Neuromyelitis Optica Spectrum Disorder	23-10-18
AstraZeneca drug Solaris approved in China as NMOSD treatment	23-10-18
AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China	23-10-18
AstraZeneca working with FDA on Ultomiris risk evaluation changes	23-09-06
Aquaporin A/S Reaffirms Earnings Guidance for the Year 2023	23-08-25
Aquaporin A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
AstraZeneca's Ultomiris wins another approval in Japan	23-05-26
AstraZeneca Wins First-in-Class Nod for Rare Inflammatory Disease Drug Ultomiris in Japan	23-05-26
Aquaporin A/S Provides Earnings Guidance of the Full Year 2023	23-05-24
AstraZeneca's Rare Inflammatory Disease Drug Wins First-in-Class EU Approval	23-05-10
AstraZeneca's ultomiris recommended for EU approval	23-04-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aquaporin A/S

Equities

AQP

DK0061555109

Other languages

Filters